Government rules changed to ensure availability of GLP-1 RAs 5 June 2024 From this week, Government rules have been changed to ensure medicines like Ozempic and Trulicity are available for the people who need them most. These medicines are called glucagon-like peptide 1 receptor agonists or GLP-1 RAs. When the government began subsidising GLP-1 RAs they could only be available if you were being treated with other diabetes medicines (like metformin, insulin, etc) and the other medicines weren’t working to reduce your blood glucose, or you had a reaction. However, data shows that people were being prescribed GLP-1 RAs outside of these rules. In order to deal with this, the rules have been changed to: Increase access by only requiring one other medicine to have been tried (e.g. metformin), and Require doctors to get phone authorization before they can prescribe GLP-1 RAs to new users. If you’re already on Ozempic or another GLP-1 RA and it is funded through the government, these new rules shouldn’t affect you. We know that GLP-1 RAs are in short supply, and we don’t think these rules will have an immediate effect on your ability to get access to these medicines. More information is available from the PBS website.
Media releases 24 February 2026 Diabetes sector stands together in call for affordable access to technology The diabetes sector across Australia has come together to call for better access to life-changing diabetes technologies. Ahead of the... Continue Reading
Media releases 20 February 2026 Diabetes Australia appoints first Chief Health Officer Diabetes Australia has appointed Brett Fenton as its first Chief Health Officer marking a major step in strengthening clinical leadership and improving outcomes for people living with diabetes. Continue Reading
Media releases 17 February 2026 Innovative diabetes research grants will prioritise lived experiences and improve lives Innovative research projects that leverage AI technology, reduce diabetes complications, and seek to preserve and restore beta cell function are set for a $2 million investment in 2026 through the Diabetes Australia Research Trust. Continue Reading